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ABSTRACT
The majority of naturally occurring proteins are modified in some manner, with many
biological systems requiring these modifications in order to function properly.
Acylation is one such type of modification. For example, the neuropeptide ghrelin,
which plays a critical role in appetite stimulation, is octanoylated on its ser-3 residue.
Many proteins are palmitoylated at one or more cysteine residues, with the lipid moiety
essential for membrane binding. It is likely that many biological systems rely on protein
acylations, and it would be beneficial to develop techniques that allow a facile detection
of naturally occurring acylations.
Synthetically acylated peptides and proteins (a class of monodisperse polymer) have
many potential uses. Synthetically acylated peptides and proteins are being developed
for use as therapeutic agents and also as chemical standards. Synthetically acylated
peptides, for example, have the potential for use as vaccines for diseases such as
hepatitis and HIV. The ability to successfully characterise these types of semi-synthetic
molecules is imperative in their development process. In this work, mass spectrometry
is explored as a means of analysing acylated peptides and proteins.
A number of synthetically acylated peptides were examined using a range of mass
spectrometry techniques in order to identify characteristic fragmentations. Acylated
peptides were fragmented using electrospray ionisation or matrix-assisted laser
desorption/ionisation combined with collisionally induced dissociation tandem mass
spectrometry, and also using matrix-assisted laser desorption/ionisation post source
decay mass spectrometry. Acylated peptides were observed to fragment in a similar
manner to their unacylated counterparts, with the degree of fragmentation observed
dependant on the length of the acyl chain (i.e. higher collision energies were required to
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illicit the same degree of fragmentation with increasing chain length). The presence of
an acylation on an N-terminal amino acid allowed the formation of a b1 product ion, not
normally observed in the spectrum of unmodified peptides. A number of useful marker
ions for acylation at serine, tyrosine and cysteine residues were observed, including,
acyl carbenium ions and acylated immonium ions. The neutral loss of the acyl moiety
was also commonly observed. The tandem mass spectrometry conditions required to
produce marker ions were explored.
Two lipopeptides, synthesised as by-products in the production of N-terminally acylated
HIV protein Nef1-6 (acyl-GGKWSK), were characterised. These lipopeptides were
found to be twelve residues long, with an unusual ether-linked kynurenine at position
seven, and contained either a stearoyl or oleoyl moiety at their N-terminal glycine
residues (ste/ole-GGKWSK-O-kyn-SKWSK). The successful characterisation of these
molecules has allowed continued investigations into their use as immunological agents.
A range of novel monodisperse polymers, acylated at their lysine residues, were
analysed intact or subsequent to enzymatic digestion, using high performance liquid
chromatography and tandem mass spectrometry. Analogous tandem mass spectra were
observed irrespective of the acylating agent, however, chromatographic elution times
were found to be dependant on the identity of the acyl moiety. Acylated lysine
carbenium ions were observed in the tandem mass spectra, 17 u lower in mass than the
calculated value for an acylated lysine immonium ion.
This work demonstrates the ability of mass spectrometry to enable the characterisation
of a wide range of acylated peptides and proteins. The use of a variety of mass
spectrometry and commonly employed analysis techniques (such as enzymatic
digestion) further aid in the characterisation of acylated peptides and proteins.
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